Live Breaking News & Updates on Ordinal Scale|Page 13
Stay updated with breaking news from Ordinal scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
1 : Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces results from the Home Cohort of its SG016 Phase II trial of SNG001 in SARS-CoV-2 infected patients and data from the combined analysis of the Hospital and Home Cohorts. SNG001 is a formulation containing IFN-beta for nebulisation, allowing it to be delivered directly into patients’ lungs. A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells. Furthermore, some people have deficiencies in antiviral IFN signalling that make them more vulnerable to spread of the virus from the nose into the lungs where it can cause severe breathing difficulties. These findings provide a rationale to deliver IFN-beta directly to the surface epithelial cells of the lungs, the primary site of virus infection in the lun ....
Posted: Mon Mar 15, 2021 10:15 am FireChick wrote: Eh, even if anime movies were nominated for the Oscars, we all know none of them will win anyway because people at the Oscars don t care about anime in any way. You seem to be forgetting that anime has won once for feature (Spirited Away) and once for short (Le Maison en Petite Cubes). Of the other four times that anime movies have gotten nominations, there s only maybe one case where the anime movie probably should have won: • Howl s Moving Castle (2005) was a decent movie but not (IMO) one of Ghibli s best or deserving of the award. ....
Proxalutamide reduces COVID-19 mortality risk by 92 percent 260 In a Phase III trial, Proxalutamide reduced mortality and expedited recovery of hospitalised COVID-19 patients in Brazil. In a clinical trial, Proxalutamide reduced COVID-19 mortality risk by 92 percent and shortened the median hospital stay of patients by nine days. The investigator-initiated trial (NCT04728802), conducted by Dr Andy Goren and Dr Flávio Adsuara Cadegiani at 12 sites in the Brazil, is a placebo-controlled, double-blinded randomised parallel assignment study. The trial has two cohorts (men and women) and two arms (Proxalutamide and control). It enrolled 588 patients, aged 18 years and older with a clinical status of 3, 4 or 5 on the WHO COVID-19 Ordinal Scale (3 = hospitalised patients not needing oxygen therapies, 4 = hospitalised patients needing oxygen by mask or nasal prongs and 5 = severely ill hospitalised patient on non-invasive ventilation or high-flow oxygen). ....
Vitamin D supplementation found to reduce COVID-19-related mortality, says study As the coronavirus disease 2019 (COVID-19) pandemic evolves, many agents have been tested to see if they can reduce the risk of severe disease and death among infected patients. One of the widely explored agents that have been shown to reduce disease progression is vitamin D. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 is primarily a respiratory illness but is known to affect other parts of the body, from the gastrointestinal tract to the central nervous system. It can also overwhelm the immune system in severe cases, hence the scientific interest in whether immune-boosting supplementation can help fight off the infection. ....